Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials
Background Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo.Objectives We assess improvements in itch and sleep interference due to itch and their imp...
Na minha lista:
| Principais autores: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Taylor & Francis Group
2024-12-01
|
| Serier: | Journal of Dermatological Treatment |
| Fag: | |
| Online adgang: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2329240 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
